HCV animal models and liver disease

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Laurent Mailly, Mirjam B. Zeisel, Thomas F. Baumert 
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
The impact of hepatitis E in the liver transplant setting
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Volume 65, Issue 1, Pages S82-S94 (October 2016)
Inflammasomes in liver diseases
Volume 65, Issue 1, Pages S2-S21 (October 2016)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Tiny RNA with great effects: miR-155 in alcoholic liver disease
Stuart J. Forbes, Sanjeev Gupta, Anil Dhawan  Journal of Hepatology 
Volume 68, Issue 5, Pages (May 2018)
Anatoliy I. Masyuk, Tatyana V. Masyuk, Nicholas F. LaRusso 
The impact of hepatitis E in the liver transplant setting
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
NS5A inhibitors in the treatment of hepatitis C
Volume 65, Issue 1, Pages S82-S94 (October 2016)
Immigration and viral hepatitis
Determinants of hepatic effector CD8+ T cell dynamics
Heidi Barth, Eric Robinet, T. Jake Liang, Thomas F. Baumert 
Ype P. de Jong, Charles M. Rice, Alexander Ploss  Journal of Hepatology 
Allogeneic hematopoietic cell transplant in HCV-infected patients
Living donor liver transplantation: is the hype over?
Thomas F. Baumert, Catherine Fauvelle, Diana Y. Chen, Georg M. Lauer 
David G. Bowen, Christopher M. Walker  Journal of Hepatology 
Mesenchymal stromal cell therapy for liver diseases
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Biology of the immunomodulatory molecule HLA-G in human liver diseases
Hepatitis C core protein – The “core” of immune deception?
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Burcin Ekser, Eric Lagasse  Journal of Hepatology 
Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 45, Issue 4, Pages (October 2006)
Liver is liver and blood is blood, and finally the twain have met
Ribavirin ante portas: Uptake transporters into hepatocytes dissected
Genomic risk of hepatitis C-related hepatocellular carcinoma
Darius Moradpour, Arash Grakoui, Michael P. Manns 
Autophagy in the liver Journal of Hepatology
Volume 43, Issue 4, Pages (October 2005)
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
EASL Clinical Practice Guidelines: Wilson’s disease
Volume 61, Issue 1, Pages S45-S57 (November 2014)
Stephen Locarnini, Angelos Hatzakis, Ding-Shinn Chen, Anna Lok 
Induced pluripotent stem cells: A new era for hepatology
S. Tamir Rashid, Graeme J.M. Alexander  Journal of Hepatology 
Volume 57, Issue 5, Pages (November 2012)
Cédric Coulouarn, Bruno Clément  Journal of Hepatology 
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
Volume 61, Issue 1, Pages S79-S90 (November 2014)
miR-122 – A key factor and therapeutic target in liver disease
Immigration and viral hepatitis
The potential of induced pluripotent stem cell derived hepatocytes
Kornelius Schulze, Jean-Charles Nault, Augusto Villanueva 
Global burden of alcoholic liver diseases
HCV targeting of patients with cirrhosis
Volume 63, Issue 1, Pages (July 2015)
Familial amyloidosis: Great progress for an orphan disease
Tatiana Kisseleva, David A. Brenner  Journal of Hepatology 
Liver transplantation in children
Pathogenesis of cholestatic hepatitis C
Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing  Roongruedee Chaiteerakij,
Chimeric mouse model of hepatitis B virus infection
Eric Robinet, Thomas F. Baumert  Journal of Hepatology 
Genetics of hepatocellular carcinoma: The next generation
Volume 64, Issue 6, Pages (June 2016)
Reversion of disease manifestations after HCV eradication
Presentation transcript:

HCV animal models and liver disease Koen Vercauteren, Ype P. de Jong, Philip Meuleman  Journal of Hepatology  Volume 61, Issue 1, Pages S26-S33 (November 2014) DOI: 10.1016/j.jhep.2014.07.013 Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Different approaches to create mouse models for the study of HCV. Left panel: In vitro adaptation of HCV to mouse hepatoma cells may allow the isolation of viral variants that can establish an infection in wild type mice. Middle panel: Transient or stable expression of viral genes may provide essential information on viral protein-host interactions. In addition, mice can be made transgenic for human factors that are essential to support infection of wild type HCV. Right panel: In xenotransplantation models, the genetic background of the host permits repopulation of the liver upon transplantation of human hepatocytes. Additional transplantation of HLA-compatible hematopoietic stem cells may result in dually reconstituted mice. Journal of Hepatology 2014 61, S26-S33DOI: (10.1016/j.jhep.2014.07.013) Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2014 61, S26-S33DOI: (10. 1016/j. jhep. 2014. 07 Copyright © 2014 European Association for the Study of the Liver Terms and Conditions